Funding for this research was provided by:
Cancer Research UK (A18349)
Received: 21 March 2019
Accepted: 28 March 2019
First Online: 14 June 2019
Ethics approval and consent to participate
: The trial has received ethics approval from the NHS National Research Ethics Service (NRES) East Midlands-Leicester South (15/EM/0455). All participants provide full informed consent to participate in SEL-I-METRY.
: Not applicable.
: SRB, AH, HB, LF, KF, LM, RG, YD and GF declare that they have no competing interests. JW has previously received honoraria for attending Advisory Boards for both AstraZeneca and Sanofi-Genzyme and has received honoraria/support to attend educational meetings from Eisai, Bayer and Sobi. KN has received honoraria for teaching and consultancy from Eisai, AstraZeneca, Sanofi-Genzyme and Sobi. DGdC has received honoraria, consultancy and speaker fees as well as research funding from AstraZeneca.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.